Quantitation of tumor vessel density in CD31 immunostained sections revealed ~60–80% reduction in vessel area in either LLC (Fig. 2D) or B16-F10 (Supplementary Fig. 10F–I) tumor allografts from Cds2 vMO-treated animals compared to controls. This evidence concerns the gene CDS2 and neoplasm.